cbdMD saw Q4 revenue increase slightly while cutting operating and net losses, aided by disciplined cost management. The company ended the year with improved margins and a strengthened balance sheet.

cbdMD generated $4.6 million in revenue during Q3 2025, with a net loss of $1.23 million. The company experienced lower gross profit margins and higher operating losses, despite growth in its e-commerce segment and expansion of its Oasis beverage distribution.

cbdMD reported $4.75 million in revenue in Q2 2025, up 8.6% YoY. Gross margin improved to 62%, and operating loss narrowed significantly. The company completed a capital restructuring and maintained strong direct-to-consumer sales while gaining momentum in new product lines like Herbal Oasis.

cbdMD reported total net sales of $5.1 million for the three months ended December 31, 2024, a decrease of 4.9% year-over-year. Despite the sales decline, the company achieved a net income of $15,095 and positive Adjusted EBITDA of $214,817. This performance was attributed to optimizing product portfolio, right-sizing cost structure, and investing in marketing, with wholesale sales showing a positive impact and the launch of a new beverage line.

cbdMD, Inc. reported net sales of $10.6 million for the third quarter of fiscal 2021, remaining steady year-over-year. The company announced earnings of $.02 per share for the quarter. However, due to product production delays from vendors on new product launches, the company reduced its Q1 fiscal 2022 net sales guidance to a range of $14.9 million to $15.5 million.

cbdMD, Inc. reported a 26% increase in net sales for the second quarter of fiscal year 2021, reaching $11.8 million, driven by growth in both e-commerce and wholesale channels. The company launched new products and expanded its marketing and sponsorship programs.

Paw CBD, cbdMD's pet CBD brand, experienced a 64% increase in net sales, growing from approximately $750,000 in the March 2020 quarter to approximately $1,229,000 in the June 2020 quarter.